Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667654 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)
A Phase 2 study, sponsored by Centrexion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT00667654 is a Phase 2 study that has completed, run by Centrexion Therapeutics. The registered enrollment target is 54 participants.
The verdict
NCT00667654, a Phase 2 study, has completed, sponsored by Centrexion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
This study will evaluate dosing regimens of 4975 in terms of safety and tolerability when delivered as an intra-articular injection in the knee. Secondary objectives will be to explore the efficacy of 4975 in terms of onset, extent and duration of pain relief.
Interventions
- DRUG CNTX-4975
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2007-08 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00667654
The ClinicalTrials.gov registry entry for NCT00667654 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centrexion Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CNTX-4975 is the first listed.
NCT00667654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00667654 about?
NCT00667654 is a clinical study titled "Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)". This study will evaluate dosing regimens of 4975 in terms of safety and tolerability when delivered as an intra-articular injection in the knee. Secondary objectives will be to explore the efficacy of 4975 in terms of onset, extent and duration of pain relief.
What is the current status of trial NCT00667654?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2007-08. Estimated completion is 2016-08.
What interventions are being tested in trial NCT00667654?
The interventions under investigation include: CNTX-4975 (DRUG).
Who is sponsoring clinical trial NCT00667654?
This trial is sponsored by Centrexion Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.